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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Ionis Pharmaceuticals has made two positive announcements
about the historic Phase 1 clinical trial of its gene-silencing drug
for Huntington’s disease: trial enrollment is complete, and the
company will extend the study for all patients who complete Phase
1.
These are key steps on a multi-year path to possible Phase 2 and 3
trials that, if successful, would bring the trial drug, IONIS-HTTRx,
to market. Typically, all three phases of a clinical trial project take
at least five years, although nobody can predict the actual course
of a trial.
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IONIS-HTTRx aims to alleviate HD symptoms by reducing
production of the huntingtin protein in brain cells (click here to
read more). Ionis launched the Phase 1 trial in September
2015. Three dozen patents are taking part in the trial, expected to
be completed by the end of 2017, at sites in Canada, Germany, and
England. This first phase aims not to assess success in combating
HD but rather simply whether the drug is safe and tolerable.
It marks the first time HD patients are receiving a substance aimed
to attack the genetic causes of the disease. It’s also the first time
they’re getting a drug via spinal injection.
“The safety and tolerability profile of IONIS-HTTRx in the
completed cohorts of the Phase 1/2a study supports its continued
development,” a June 22 Ionis news release stated. “Patients who
complete the Phase 1/2a study will be eligible to participate in an
open-label extension (OLE) study that Ionis plans to initiate in the
next several months.”
“Open label” means all participants take the drug, in contrast with
a “double-blinded” clinical trial like the current Phase 1, where
half the patients receive a placebo and neither patients nor doctors
know who is receiving the actual drug.
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This month’s news provided the strongest indication so far that
Ionis and its partner Roche, a much larger multinational
pharmaceutical firm with vast clinical trial experience, will take
IONIS-HTTRx into a larger, critical Phase 2 study, as early as
2018, to measure efficacy.
“Upon completion and full analysis of this study, the next step for
this program will be to conduct a study to investigate whether
decreasing mutant huntingtin protein with IONIS-HTTRx can slow
the progression of this terrible disease," Frank Bennett, Ph.D., the
Ionis senior vice president of research, said in the release.
Ionis has repeatedly indicated that a Phase 2 study would include
U.S. trial sites.

Frank Bennett, Ph.D. (photo by Kristina Bowyer, Ionis)
‘Cautiously optimistic news’
The double-blinded protocol of the Phase 1 HTTRx trial insures
that bias and other external factors don’t affect the trial results.
As noted, in an OLE each participant receives the actual drug, and
usually at the highest dose tried in Phase 1. An OLE allows
researchers to gather more data, examine the drug’s effects over a
longer period of time, and better prepare for an eventual Phase 2.
Patients also potentially benefit by receiving the drug longer.
curehd.blogspot.com/2017/06/ionis-huntingtons-disease-drug-step.html
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The HD research website HDBuzz, which is produced by
clinicians and scientists, described the Ionis announcements as
“cautiously optimistic news.”
“News that the trial is fully recruited and the final patients are
going through the procedures is a strong suggestion that even at
the highest doses, the drug’s safety looks good,” the HDBuzz
report observed. “Despite exhaustive safety testing before going
into patients, any drug can produce unwanted effects, so that’s
really the best news we could be hoping to hear at this stage.”
Regarding the open-label extension, it added, “We don’t want to
read too much into a brief announcement, but running an OLE
isn’t cheap for a trial sponsor, so this announcement certainly
gives us optimism about the whole HTTRx program.”
Signs of HD in the blood
A separate research study, with results published June 7, could
help Ionis and Roche researchers evaluate the results of the Phase
1 trial and plan the potential Phase 2 trial.
In what was described as a “major advance in the field of
Huntington's disease and neurodegeneration in general,” a team of
researchers has identified a potential blood biomarker for HD.
Biomarkers indicate a disease mechanism or drug impact. They
are common for many diseases, but the complexity and
inaccessibility of the brain have made it extremely difficult for
researchers to find them for neurological diseases.
HD scientists have most recently focused on obtaining biomarkers
from the cerebral spinal fluid (CSF). However, obtaining CSF,
which requires puncturing the spine, is far riskier than drawing
blood, the technique used in the new biomarker research.
Led by Ed Wild, M.D., Ph.D., one of the administrators of the
IONIS-HTTRx trial in England, the new biomarker study
demonstrated that a brain protein known as neurofilament light
chain (Nfl) appears in the blood of HD patients and
presymptomatic gene carriers. (Click here and here to read more.)
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Dr. Ed Wild (photo from EdWild.com)
A less invasive measurement
Dr. Bennett of Ionis previously described Nfl as a protein involved
in the cytoskeleton, or internal “scaffold,” of neurons. HDBuzz
likened it to “the ribs of an umbrella.”
Dr. Wild’s team discovered that, the more advanced the stage of
HD, the greater the amount of Nfl in the blood.
“This suggests that a blood test might be able to provide consistent
information about the brain, in place of an invasive spinal tap,”
HDBuzz commented. “We hope [Nfl] will be added to the arsenal
of resources that are helping us to monitor HD and to develop new
therapies.”
Indeed, the IONIS-HTTRx researchers previously noted that Nfl is
one potential biomarker in the Phase 1 trial.
Further research is underway to confirm the Wild team's results
and to determine to what extent Nfl can be used as a biomarker.
Pope Francis, Ionis, and the hope for a cure
The Ionis announcements about the clinical trial came as the 32nd
annual convention of the Huntington’s Disease Society of America
got underway in Schaumberg, IL. In addition to the news release,
Ionis issued a letter to the HD community.
“We can assure you our number one goal remains our commitment
to advancing IONIS-HTTRx development, a drug that has the
potential to transform the treatment of HD,” the letter stated.
curehd.blogspot.com/2017/06/ionis-huntingtons-disease-drug-step.html
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The positive news also comes in the wake of HDdennomore, the
historic audience of the Huntington’s disease community with
Pope Francis in Rome on May 18.
Dr. Bennett made a substantial donation to HDdennomore. He and
several Ionis officials attended the audience. Dr. Bennett and his
wife Paula sat in the front row along with leading HD scientists
and dignitaries. They were greeted by Francis.
In his address, the pope recognized the geneticists and scientists
“present here, who, for some time, sparing no energy, have
dedicated themselves to studying and researching a treatment for
Huntington’s disease. Clearly, there is a great deal of expectation
surrounding your work: resting on your efforts are the hopes of
finding the way to a definitive cure for the disease, but also of
improving the living conditions of these brothers and sisters, and
of accompaniment, especially in the delicate phases of diagnosis,
at the onset of the first symptoms.”
If it succeeds, IONIS-HTTRx could fulfill those hopes and show
the way to curing other neurological diseases.

Frank Bennett (left), Paula Bennett, and Gene Veritas (aka
Kenneth P. Serbin) in St. Peter’s Square just before the audience
with Pope Francis, May 18, 2017 (photo by Bianca Serbin)
(Disclosure: I hold a symbolic amount of Ionis shares.)
(Click on the links below for past coverage of the Ionis HD
project.)
Ionis Phase I Huntington's disease clinical trial at halfway mark:
'No surprises so far' means good news
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Chief Huntington's disease drug hunter: 'every confidence first
treatments' in the works
Huntington's disease patients get first dosing in historic Isis
Pharmaceuticals' gene-silencing drug trial
Isis Pharmaceuticals launches historic clinical trial to silence
Huntington's disease gene
Moving toward a potential treatment: Isis, CHDI researchers
outline upcoming Huntington's disease clinical trial
A key new ally in the search for Huntington's disease treatments
Quickening the pace towards a Huntington's disease genesilencing clinical trial: pharma giant Roche, Isis enter partnership
Designing the best drug possible to defeat Huntington's disease
Building a 'laser-guided missile' to attack Huntington's disease
Observing the cure in progress
Posted by Gene Veritas at 11:42 AM
Labels: biomarkers , cerebral spinal fluid , clinical trials , Frank Bennett , gene
silencing , huntingtin , Huntington's disease , Ionis Pharmaceuticals , IONIS-HTT-Rx ,
neurofilament , open-label extension , safety , tolerability

2 comments:
Bev said...
Thank you for once again giving us, your readers, a cogent
explanation of the research that gives us all reason for hope.
This Ionis gene-silencing drug has my hopes up.
6:48 PM, June 27, 2017

Akila Ramanathan said...
Thank you Gene veritas for your updated information
regarding ionis clinical trials indeed it's a good news. Hope it
will continue & boon to hd patients
9:39 PM, June 27, 2017
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